NCT00003174View on ClinicalTrials.gov

Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 1998

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Leukemia
Interventions
DRUG

bryostatin 1

DRUG

cladribine

Trial Locations (3)

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

48236

Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods

48202-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00003174 - Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter